文献速递新发突发、热带与寄生虫病

重新考虑高传播地区对缓慢消除抗疟药耐药性的临床评估

Reconsidering the clinical assessment of resistance to slowly eliminated antimalarial drugs in high-transmission settings.
PubMed 文献 · Lancet Infect Dis · 2025-09-30

本文指出WHO推荐的治疗效果监测(TES)在高传播地区存在局限性,易高估治疗失败并漏判再感染导致的早期复发。作者建议在哨点机构记录过去3周内接受完整青蒿素联合疗法(ACT)的有症状疟疾患者比例,若超过暂定5%阈值,则对全部此类患者进行干血斑药物浓度测定和PCR寄生虫检测。耐药定义为药物浓度达标时PCR确认的寄生虫血症。该方法较TES更简便、可部署、低成本、敏感、通用且准确。

要点

  • TES在高传播地区易高估治疗失败并漏判再感染。
  • 建议哨点监测3周内ACT用药比例,超5%阈值时检测。
  • 耐药定义为药物浓度达标时PCR确认的寄生虫血症。

核心结论

  • 建议的哨点监测方法较TES更简便、可部署、低成本、敏感、通用且准确,用于识别缓慢消除抗疟药的新发耐药。

研究设计与样本

  • 本文为观点/建议类文章,提出替代TES的哨点监测方法,未报告样本量。

主要发现

  • TES在高传播地区易高估治疗失败并漏判再感染导致的早期复发。
  • 建议哨点记录过去3周内接受完整ACT的有症状疟疾患者比例。
  • 若该比例超过暂定5%阈值,则对全部此类患者进行干血斑药物浓度测定和PCR检测。
  • 耐药定义为药物浓度达标时PCR确认的寄生虫血症。

关键数值与推荐

  • 阈值暂定为5%。
  • 耐药定义为药物浓度达标时PCR确认的寄生虫血症。

临床怎么用

  • 在哨点机构监测3周内ACT用药比例,超5%阈值时对全部此类患者检测药物浓度和PCR。
  • 该方法可促进以寄生虫密度为表型、校正药物浓度的全基因组关联研究。

局限性

  • 5%阈值为暂定值。
  • 方法为建议性,未报告验证数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapeutic efficacy surveillance (TES) is the current WHO recommended method of assessing antimalarial treatment efficacy in vivo. TES has considerable limitations: it is logistically demanding, expensive, can only be conducted in a few sites, and is underpowered, and therefore, has low sensitivity for detecting emerging resistance. In high transmission settings, TES tends to overcall treatment failure and misses earlier recurrence caused by reinfection, which is the key identifiable feature of emerging resistance to slowly eliminated antimalarial drugs. We suggest an alternative approach to TES. At sentinel sites, the proportion of patients with symptomatic malaria who received a full artemisinin-based combination therapy course within the previous 3 weeks should be recorded. If this proportion exceeds a threshold (provisionally set at 5%), capillary blood spots dried on filter paper are taken for measurement of drug levels and PCR for malaria parasite identification and quantitation on all such patients. Resistance is defined by PCR-confirmed parasitaemia in the presence of therapeutic drug levels. This approach also facilitates conduct of genome-wide association studies with parasite density as the phenotype, adjusted for drug level. Compared with TES, our suggested approach should be a simpler, more readily deployable, less expensive, more sensitive, more generalisable, and more accurate method of identifying and characterising emerging resistance to slowly eliminated antimalarial drugs.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. White NJ, Watson JA. Reconsidering the clinical assessment of resistance to slowly eliminated antimalarial drugs in high-transmission settings. Lancet Infect Dis. 2025. PMID: 41043443. doi:10.1016/S1473-3099(25)00435-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。